Exciting News: ArtiQ Joins Forces with Clario to Transform Respiratory Solutions! 

We are thrilled to announce that ArtiQ has been acquired by Clario, a leading healthcare research and technology company renowned for its groundbreaking contributions to clinical evidence generation. United, we will further transform the respiratory market and foster a positive impact beyond the scope of respiratory care. 

Only five years after its founding, ArtiQ, a spin-off from KU Leuven, is being acquired to accelerate its impact on healthcare and clinical trials markets. ArtiQ was founded in 2019 as a KU Leuven and BREATHE research group spin-off by Marko Topalovic, Wim Janssens, Bart Swaelens and Marc Decramer. All founders with strong background and commitment in the respiratory and healthcare world. 

This acquisition comes at the moment of ArtiQ’s evident impact on respiratory market and will further accelerate growth across the world and across all pharmaceutical sponsors who are developing respiratory treatments. With this acquisition, Clario’s respiratory devices will seamlessly integrate with ArtiQ’s advanced AI models, empowering clinicians with instant feedback on test quality. This integration promises to expedite the delivery of faster, more reliable data for sponsors while enhancing the overall patient experience. 

All ArtiQ products will remain on the market and receive even greater exposure. We will be intensifying the promotion of our clinical research line to reach more pharmaceutical companies. Additionally, our healthcare product line will receive enhanced support as we continue to advance our AI technology for the early and accurate detection of respiratory diseases. 

In addition to continuing to lead ArtiQ, Marko Topalovic CEO at ArtiQ, will step in to lead Clario’s overall AI strategy across the organization. Of the acquisition, he said: “Joining forces with Clario is a pivotal moment for ArtiQ. Our technology’s integration into Clario’s portfolio not only enhances the quality and efficiency of spirometry data analysis but also marks a sizable step toward minimizing the patient burden and improving trial outcomes. He added: “This acquisition is a testament to the hard work and dedication of ArtiQ’s amazing team. The team’s commitment has been the driving force behind all our achievements, and with such a strong team, ArtiQ will continue to thrive and flourish in the future.” 

“We’re thrilled to welcome ArtiQ into our organization,” said Chris Fikry, CEO at Clario. “Since 2018, Clario has been a pioneer in applying artificial intelligence with a human touch to transform clinical trial endpoint analysis. This move significantly advances AI within our respiratory portfolio. With ArtiQ’s technology, we are expanding our ability to rapidly scale AI for overreading while ensuring data quality and streamlining the clinical trial process for patients around the world.” 

Success of ArtiQ also highlights trust and support given on this remarkable journey by KU Leuven, University Hospitals Leuven, and the early investors Gemma Frisius Fund and KBC Focus Fund.  

We are genuinely excited to embark on this new journey alongside Clario, leveraging our combined strengths to introduce unparalleled solutions that will revolutionize respiratory care and elevate patient outcomes worldwide. Stay tuned for the innovations that lie ahead! 

About Clario 

Clario is a leading healthcare research and technology company that generates the highest quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints.    

Clario’s global team of science, technology, and operational experts have helped deliver over 26,000 trials and contributed to over 800 regulatory approvals in more than 100 countries. For more than 50 years, we have delivered deep scientific expertise and the broadest endpoint technologies to help transform lives around the world.       

For more information, go to Clario.com or LinkedIn and Twitter.  

About ArtiQ 

ArtiQ is a leading innovative software company that spun off from the Belgian university KU Leuven, dedicated to enhancing the diagnosis and monitoring of patients with respiratory conditions. Moreover, ArtiQ strives to streamline and optimize respiratory clinical trials for pharmaceutical companies. Through the development and provision of cutting-edge AI-first software, ArtiQ empowers traditional respiratory devices and processes. 

ArtiQ was launched in 2019 with the support of KU Leuven, University Hospitals Leuven, and the early investors Gemma Frisius Fund and KBC Focus Fund. Since then, together with researchers, clinicians, equipment manufacturers, and pharmaceutical companies, we are on a mission to make key improvements for patients with lung diseases.  

More information can be found at artiq.eu or on LinkedIn and Twitter.